Genialis, a leader in applied data science for the development of precision medicines, today announced a collaborative partnership with OncXerna, an international, clinical-stage biopharma developing next-generation immunotherapies for cancer. Early work between the two companies has thus far focused on modeling gene expression signatures predictive of treatment for gastric cancer. The patent-pending enhanced methodology will further OncXerna’s clinical development plans to expand beyond gastric cancer to other tumor microenvironment phenotypes.

Read the press release in its entirety here.

Share this story, choose your platform!